Evaluation of the Efficacy and Treatment-Emergent Adverse Events of Deuruxolitinib for Moderate to Severe Alopecia Areata: A Dose-Ranging Meta-Analysis of 1,372 Randomized Patients

    October 2025 in “ Frontiers in Medicine ”
    Mulham Kalantan, Bader Bashrahil, Abdulaziz Aljuaid … Abdulhadi Jfri
    Studysummary This study found that deuruxolitinib may effectively improve hair regrowth and patient satisfaction in moderate to severe alopecia areata, but careful monitoring is needed due to manageable side effects and concerns about long-term safety.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on frontiersin.org →
    Discuss this study in the Community →

    Research cited in this study 18

    1. Efficacy and Safety of Deuruxolitinib, an Oral Selective Janus Kinase Inhibitor, in Adults with Alopecia Areata: Results from the Phase 3 Randomized, Controlled Trial (THRIVE-AA1) Journal of the American Academy of Dermatology · 2024
    2. Janus Kinase Inhibitors For Alopecia Areata JAMA network open · 2023
    3. The Evaluation of JAK Inhibitors on Effect and Safety in Alopecia Areata: A Systematic Review and Meta-Analysis of 2018 Patients Frontiers in immunology · 2023
    4. Efficacy and Safety of Different JAK Inhibitors in the Treatment of Alopecia Areata: A Network Meta-Analysis Frontiers in immunology · 2023
    5. Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-Analysis Acta dermato-venereologica · 2023
    6. The Efficacy and Safety of JAK Inhibitors for Alopecia Areata: A Systematic Review and Meta-Analysis of Prospective Studies Frontiers in pharmacology · 2022
    7. Selective Inhibition of JAK3 Signaling Is Sufficient to Reverse Alopecia Areata JCI insight · 2021
    8. A Phase 2a Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of the Oral Janus Kinase Inhibitors Ritlecitinib and Brepocitinib in Alopecia Areata: 24-Week Results Journal of the American Academy of Dermatology · 2021
    9. JAK Inhibitors for Alopecia Areata: A Systematic Review and Meta-Analysis JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology · 2019
    10. Prevalence of Pediatric Alopecia Areata Among 572,617 Dermatology Patients Journal of the American Academy of Dermatology · 2017
    11. The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm Advances in Therapy · 2017
    12. JAK Inhibitors in Dermatology: The Promise of a New Drug Class Journal of the American Academy of Dermatology · 2017
    13. Epidemiology and Burden of Alopecia Areata: A Systematic Review Clinical, Cosmetic and Investigational Dermatology · 2015
    14. Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition Nature medicine · 2014
    15. Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis Journal of Investigative Dermatology · 2014
    16. Current Treatment of Alopecia Areata ˜The œjournal of investigative dermatology. Symposium proceedings/˜The œJournal of investigative dermatology symposium proceedings · 2013
    17. Genome-Wide Association Study in Alopecia Areata Implicates Both Innate and Adaptive Immunity Nature · 2010
    18. Alopecia Areata: Overview and Treatment Options International Journal of Dermatology · 2007